BRAINIACS
BRAIN IMAGING AND COMPUTING SCIENCES

2025 Volume 6
Issue 3 Edoc B3D757EF9

From Play to Precision Care: Clinical Telegaming Biomarkers to Evaluate Medication Efficacy for Improving Multiple Sclerosis Patients' Quality of Life*

Kento Shigyo, Adam Craig, Carl Taswell†

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by progressive deterioration of motor, sensory, cognitive, and social functioning. Its relapsing and heterogeneous nature means that symptom severity and trajectory vary across patients, often leading to long-term declines in independence and quality of life in daily living. Disease-modifying therapies (DMTs) aim to slow this progression and support functional recovery, with efficacy monitored through periodic clinic visits that inform treatment adjustments. While DMTs have demonstrated efficacy in reducing relapse rates and slowing disability progression at the population level, determining which medications are most effective for individual patients remains challenging due to the heterogeneity of MS symptoms and treatment responses. Current clinic-based evaluations provide only infrequent snapshots of patients' functioning, often missing the fatigue, cognitive lapses, and social withdrawal that manifest under the demands of everyday life. Without continuous and timely data on these aspects, clinicians lack the granular evidence needed to detect subtle treatment responses or adjust therapies in a timely manner. To address this problem, we apply the framework of clinical telegaming as a complementary assessment platform that bridges home-based and in-clinic evaluation for individuals living with MS. By delivering structured, interactive games via augmented or mixed-reality displays in everyday environments, the system captures motor-sensory and social-behavioral interaction data to generate digital biomarkers. These biomarkers aim to complement existing clinical assessments, enabling timely and comprehensively evaluation of medication efficacy and quality-of-life outcomes in support of precision care. We expect this approach to yield clinically meaningful digital biomarkers that continuously and individually capture how MS affects patients' daily functioning, providing a richer record of treatment response than clinic visits alone can offer. By bridging in-clinic assessments and everyday functioning, the proposed telegaming telecare system would have the potential to support more informed, timely, and cost-efficient treatment decisions, ultimately contributing to more precise patient-centered MS care.

Keyphrases

Multiple sclerosis, clinical telegaming, digital biomarkers, precision care, individualized treatment, quality of life.

Contents

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease affecting motor, sensory, social, and cognitive functioning (Friedrich 2023), often diminishing independence and quality of life (Gómez-Melero et al. 2024). Disease-modifying therapies (DMTs) are pharmacologic treatments that aim to slow progression and support functional recovery of MS (Goodin et al. 2002). However, determining which medications work best for individual patients and monitoring their effects over time remains challenging (Pathak 2023). Moreover, current assessments for DMTs, which are typically brief, clinic-based evaluations, provide valuable insights into motor performance but rarely capture the social, affective, and cognitive dimensions that shape quality of life, underscoring the importance of evaluating daily functioning holistically. The World Health Organization defines quality of life as "an individual's perception of their position in life in the context of the culture and value

* Report presented 2025-10-09, Guardians 2025, 4th BHAVI Guardians Conference.
† Correspondence to kshigyo@bhavi.us.



Figure 1: Overview of the proposed clinical telegaming framework for precision care in multiple sclerosis. Home-based gameplay captures motor, sensory, and social interaction data, which are transformed into digital biomarkers to support individualized (N-of-1) treatment decisions and improve quality of life.

systems in which they live, and in relation to their goals, expectations, standards, and concerns" (WHOQOL Group 1994).

DMTs for MS are among the most expensive chronic therapies in medicine, with annual costs often exceeding USD $70,000–$90,000 per patient (Hartung 2021). When an ineffective medication goes undetected due to infrequent clinic visits, continued treatment wastes financial resources that can accumulate to tens of thousands of dollars within just a few months. Beyond economic burden, prolonged exposure to ineffective drugs increases risks of adverse effects, reduces adherence, and undermines patient trust. These challenges underscore the need for timely, objective, and clinically valid indicators of treatment efficacy, enabling clinicians to make informed, cost-efficient decisions about which medications best serve individual patients, advancing toward precision care.

Clinical telegaming (Taswell 2010b; Lockery et al. 2011; Xu et al. 2015) offers a platform to provide such indicators by capturing real-world performance metrics that can support earlier and more accurate risk–benefit analysis. Additionally, it provides a non-stigmatizing, game-based environment that integrates naturally into everyday life, emphasizing quality of life rather than mental health labeling, which is an important consideration in MS care.

To achieve this goal, we plan to apply the established paradigm of clinical telegaming to evaluate treatment efficacy and quality of life in MS. Clinical telegaming in our study will consist of structured, interactive games delivered at home via augmented displays, mixed-reality systems, or repurposed commercial video games. By capturing motor-sensory and social-interaction metrics during naturalistic, engaging tasks in clinical telegaming, we aim to generate and extract digital biomarkers that complement existing clinical assessments for DMTs. In doing so, we reposition clinical telegaming not merely as a therapeutic tool, but as a rigorous assessment modality grounded in clinical validity and patient-centered design. This approach does not replace clinician expertise, but it aims to provide richer, continuous evidence to support precision care.

Related Work

This section reviews prior work in two domains relevant to our system: (1) digital biomarkers, including their definition, clinical motivations, and methods of collection, and (2) clinical telegaming, a growing approach for remote assessment and rehabilitation. Together, these strands of research highlight opportunities for leveraging game-derived behavioral data as digital biomarkers for monitoring disease progression and treatment response in MS.

Digital Biomarker

The US National Institutes of Health and the US Food and Drug Administration define a biomarker as "a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention, including therapeutic interventions" (Group et al. 2016). In addition, a number of categories of biomarkers have been defined according to their purposes and applications with some overlaps: 1) diagnostic biomarker, 2) monitoring biomarker, 3) pharmacodynamic/response biomarker, 4) predictive biomarker, 5) prognostic biomarker, 6) safety biomarker and 7) susceptibility/risk biomarker (Califf 2018). These biomarkers serve as reporting indicators and measures across diagnosis, disease monitoring, treatment decision-making, and risk stratification, thereby building the foundation for precision care. This biomarker reporting foundation remains especially important for complex, multifactorial, and multidimensional conditions such as MS.

However, collecting these biomarkers can be time-consuming when it requires the direct involvement of physicians or other healthcare professionals (Dillenseger et al. 2021). Moreover, a growing body of research has highlighted that clinic-based assessments overlook the lived experiences of patients and often do not reflect their real-world functioning (Shiffman et al. 2008). These limitations have motivated a shift toward digital biomarkers, which enable continuous and ecologically valid data collection in patients' everyday environments.

The term digital biomarker refers to "objective, quantifiable physiological and behavioral data that are measured and collected by digital devices" (Dillenseger et al. 2021). Digital biomarkers are typically collected through sensors embedded in smartphones, wearables, and other connected devices, capturing physiological signals (e.g., heart rate, gait characteristics) and behavioral patterns (e.g., mobility, interaction behaviors) in real-world environments (Coravos et al. 2019). These passive and active monitoring approaches will allow continuous, longitudinal assessment with low burden on patients and clinicians.

Clinical Telegaming

An emerging approach to collecting digital biomarkers is the use of clinical telegaming, defined as "a medical subspecialty focused on delivery of telecare involving diagnostic and therapeutic telegaming" (Taswell 2010b). Prior to the formalization of clinical telegaming, game-based and remote rehabilitation approaches had been explored for conditions such as post-stroke recovery and upper-limb dysfunction, including haptic home-based telerehabilitation (Jadhav et al. 2006) and virtual environment-based remote therapy for stroke patients (Holden et al. 2007). Game-derived measures offer a promising pathway for developing digital biomarkers that capture fine-grained motor, cognitive, and behavioral signals in home settings. Compared to traditional clinical assessments, these measures are potentially useful to provide ecologically valid insights, as they are collected during activities that

more closely resemble activities of daily living (ADLs).

Early work on clinical telegaming focused on infrastructure and resource management. Taswell (2010b) integrated telegaming registries into the broader Nexus-PORTAL-DOORS-Scribe (NPDS) framework (Taswell 2007; Taswell 2010a; Dutta et al. 2020), enabling metadata management for telecare and therapeutic interventions. Lockery et al. (2011) extended this effort through the Clinical Telegaming System (CTGS), supporting both clinic-based and home-based telerehabilitation. These systems provide crucial infrastructure but do not address patient-centered outcome evaluation.

Subsequent research demonstrated telegaming's therapeutic potential for neurological disorders. Xu et al. (2015) developed a web-enabled platform to evaluate multisensory integration and responses to auditory and visual stimuli in Parkinson's disease. Broadly, telerehabilitation studies report improvements in motor and cognitive outcomes (Maggio et al. 2024), enhanced adherence and quality of life (Dhamija et al. 2025; Sharma et al. 2024), and safe long-term use across neurological populations (Peretti et al. 2017).

The term *exergame* is defined as "a video game that promotes (either via using or requiring) players' physical movements (exertion) that is generally more than sedentary and includes strength, balance, and flexibility activities" (Oh and Yang 2010). Adiwangsa et al. (Adiwangsa et al. 2025) explored its potential use in MS care through workshops involving researchers across disciplines and MS experts, and identified two key design themes: 1) the need for accessibility and equipment considerations, e.g., button placement and vertigo sensitivity, and 2) the importance of social interaction given the reduced physical accessibility experienced by people with MS. Building on these themes, Adiwangsa et al. (Adiwangsa et al. 2025) proposed design recommendations: leveraging AR HMD exergames to bridge home and clinic-based interventions, incorporating tangible objects in the home environment to enhance engagement, and enabling asynchronous interactions or virtual environments to simulate social scenarios.

Collectively, prior studies highlight the feasibility of clinical telegaming and offer design implications for rehabilitation through game-based interventions, directly informing and inspiring our proposed system. While prior work has explored games for cognitive monitoring (Pless, Woelfle, Naegelin, et al. 2023; Pless, Woelfle, Lorscheider, et al. 2025; Gromisch et al. 2025) and as rehabilitative interventions (Ortiz Gutierrez et al. 2013; Prosperini et al. 2014; Jonsdottir et al. 2018; Dalmazane et al. 2021), no existing work has leveraged telegaming-derived biomarkers specifically to evaluate medication efficacy or to systematically assess quality-of-life dimensions spanning motor, cognitive, emotional, and social domains in an integrated framework. Furthermore, the integration of telegaming biomarkers into precision-care frameworks for MS remains largely unexplored, representing a gap this work aims to address.

Research Plan

This project aims to develop a clinically validated, home-based telegaming system capable, in collaboration with MS specialists, of generating digital biomarkers that support precision care for individuals living with MS. The planned research will characterize motor, sensory, cognitive, and social–behavioral functioning through structured gameplay. Sensory, cognitive, and motor assessments will examine limb coordination, balance, movement smoothness, and reaction speed, while social–behavioral assessments will focus on cooperative play, turn-taking, and caregiver–patient coordination. These domains are central to daily functioning yet remain difficult to measure in routine clinical visits. The following indicators were selected based on their established relevance to MS-related functional impairments (Table 1).

Research Goals and Rationale

A key goal of this research is to link these behavioral signals to individual treatment trajectories, enabling digital biomarkers to serve as indicators of medication effectiveness at the level of 'N-of-1' precision care. International MS research communities have articulated several strategic priorities that guide collaborative efforts worldwide (see Table 2 for a summary of key organizations and their research priorities). The International Progressive MS Alliance (IPMSA) identifies the lack of validated biomarkers capable of detecting disease progression and treatment response as a barrier to developing effective therapies for progressive MS (Kapoor et al. 2020). Similarly, the Multiple Sclerosis International Federation (MSIF) highlights persistent global disparities in access to MS diagnosis and care (Solomon et al. 2023), and has called for greater integration of patient-reported outcome measures that reflect real-world functioning (Morra et al. 2024).

In recent years, the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the National Multiple Sclerosis Society (NMSS), and other organizations have emphasized the importance of precision medicine, including the development of predictive and prognostic biomarkers to support individualized treatment selection, as a central priority in their research roadmaps (*e.g.*, Bebo et al. 2022). These international priorities collectively reflect a broader shift from episodic, clinic-centered evaluation toward continuous, data-driven, and ecologically valid monitoring of disease impact. Furthermore, the Japan Agency for Medical Research and Development (AMED) promotes precision medicine and data-driven healthcare innovation, while the International Society for Neuroimmunology (ISNI) advances research on neuroimmunological mechanisms and clinical optimization of MS and related disorders. These national and international initiatives all emphasize the importance of integrating innovative digital technologies with rigorous clinical research infrastructure.

Our proposed clinical telegaming framework directly aligns with these goals. By capturing structured performance metrics across sensory, motor, cognitive, and social domains during engaging, home-based tasks, the system aims to generate digital biomarkers sensitive to subtle functional changes. Such measures may enable earlier identification of suboptimal treatment response and support more timely adjustment of DMTs. In addition, by leveraging widely available consumer technologies and enabling remote deployment, this approach contributes to broader efforts to reduce disparities in MS care, facilitating scalable, patient-centered monitoring across diverse healthcare systems. Rather than replacing established clinical metrics, clinical telegaming is positioned as a complementary layer of continuous functional evidence, supporting precision care, outcome innovation, and quality-of-life-oriented MS management.

Participants and Sampling

Participants will include adults diagnosed with MS and their caregivers. MS participants must meet the following inclusion criteria: (1) confirmed diagnosis of MS according to the McDonald criteria (Montalban et al. 2025), (2) aged 18 years or older, (3) sufficient cognitive function to understand and follow game instructions, and (4) sufficient upper limb function to operate a VR device. Exclusion criteria

Table 1: Digital biomarker indicators or measures, relevance to MS, and assessment tasks for clinical telegaming.

Indicator or Measure	Relevance to MS	Telegaming Task
Limb coordination	Upper limb dysfunction is a core MS disability dimension; MSFC (Fischer et al. 1999)	Reaching and manipulating virtual objects with controllers
Postural balance	Increased fall risk in MS; BBS (Berg et al. 1992), TUG (Podsiadlo et al. 1991)	Weight-shift tasks and postural adjustment during gameplay
Movement smoothness	Cerebellar ataxia affects 80% of MS patients; SARA (Schmitz-Hübsch et al. 2006)	Trajectory tracking tasks; jerk and acceleration analysis
Reaction speed	Processing speed is the most commonly impaired cognitive domain in MS; SDMT (Benedict et al. 2017)	Stimulus-response tasks with timed target selection
Affect recognition	Theory of Mind deficits are documented in MS and predict quality of life; RMET (Baron-Cohen et al. 2001)	Identifying emotional states from affect and facial expression of in-game avatars or characters
Task switching	Executive dysfunction is prevalent in MS and impairs daily activities; TMT-B (Reitan 1958)	Rule-switching tasks requiring flexible response inhibition
Caregiver–patient interaction	Dependence on caregivers reflects ADL decline in MS; FIM (Granger et al. 1986)	Collaborative gameplay requiring role division and turn-taking between patient and caregiver

Table 2: International Priorities for MS Research

Organization	Primary Research Goals	Strategic Keywords
National Multiple Sclerosis Society (USA)	Accelerate therapy development; restore lost function; improve quality of life; health equity	Precision medicine; predictive biomarkers; patient-centered outcomes; individualized treatment
Multiple Sclerosis International Federation (Global)	Reduce global inequities in MS care; early diagnosis; access to effective treatment; improve quality of life worldwide	Global equity; early intervention; data harmonization; patient advocacy
International Progressive MS Alliance (Global)	Accelerate development of treatments for progressive MS; identify mechanisms of progression; develop validated biomarkers for disease activity and treatment response	Progressive MS; neurodegeneration; fluid biomarkers; innovative trial design
European Committee for Treatment and Research in Multiple Sclerosis (EU)	Advance understanding of disease mechanisms; optimize treatment strategies; develop predictive and prognostic biomarkers	Translational research; imaging and non-imaging biomarkers; digital health; personalized care
National Institute of Neurological Disorders and Stroke (USA)	Fundamental and translational neuroscience research; biomarker discovery; neurotechnology innovation	Translational science; digital biomarkers; neurotechnology
Japan Agency for Medical Research and Development (Japan)	Promote precision medicine; integrate medical data platforms; advance innovative medical devices and digital health technologies	Data-driven medicine; digital health; translational innovation
Japanese Society for Neuroimmunology (Japan)	Advance research in neuroimmunological diseases including MS; foster interdisciplinary collaboration	Neuroimmunology; clinical optimization; biomarker research

include: (1) significant neurological or psychiatric conditions that may confound biomarker interpretation, (2) severe cognitive impairment, (3) contraindications to VR device use (e.g., epilepsy, severe vertigo), and (4) clinically unstable disease status or relapse within the preceding three months.

Caregivers of enrolled MS participants will also be invited to participate, particularly to support the assessment of caregiver–patient coordination as a dimension of social functioning. The final sample size will be determined during the design phase in consultation with MS specialists, informed by the specific biomarker domains and statistical requirements of the planned feasibility and validation studies.

Three-Phase Project Timeline

The development plan is structured across three phases as illustrated in Figure 3. The first phase will focus on the design of clinical telegaming and an initial prototype for game-based data collection, suitable for laboratory testing The second phase will emphasize algorithmic refinement and home-based feasibility testing with MS patients, examining engagement, adherence, and data quality under real-world conditions. The third phase will involve preliminary clinical validation,

Table 3: Overview of the three-phase research and development plan.

Phase 1: Framework Design	Phase 2: Biomarker Development	Phase 3: Clinical Validation
Study design: · Workshops with patients, caregivers, and clinicians · Define clinical requirements and safety constraints Prototype development: · Extract reaction, coordination, and movement features · Iterative prototype refinement · Lab-based usability and safety testing Output: · Stable prototype; · Lab usability report	Biomarker design: · Algorithm development (reaction latency, coordination, cooperative behavior) · Feature engineering robust to home environments Home-based feasibility testing: · Assess engagement, adherence, and data quality · Evaluate safety and usability · Monitor dropout and barriers to adoption Output: · Validated biomarker algorithms · Home feasibility dataset	Validity testing: · Compare telegaming biomarkers with in-clinic assessments · Evaluate reliability and convergent validity · Relate biomarkers to treatment results Clinical integration: · Recommended assessment frequency and session duration · Criteria for flagging clinically meaningful change in biomarker trajectories Output: · Validity evidence · Clinical integration guidelines

establishing the relationship between biomarker trajectories and treatment outcomes, and producing guidelines for integrating the system into clinical workflows. By the end of the project period, the goal is to deliver a scientifically grounded, clinically meaningful system that advances precision care and supports continuous monitoring in everyday environments.

Framework Design Phase 1: The first phase of the research will involve a collaborative design process with MS specialists, patients, and caregivers. This phase will define the clinical requirements, safety considerations, and design constraints necessary for creating gameplay tasks that are both engaging and clinically meaningful. Design workshops will guide the creation of early prototypes and interaction concepts, ensuring that the system reflects the needs and lived experiences of its target users. Following design recommendations from prior work (Adiwangsa et al. 2025), the potential integration of tangible objects available in patients' home environments will also be explored during design, as object manipulation has been shown to support the transfer of rehabilitation gains to activities of daily living. Whether to incorporate specialized equipment will be determined in consultation with MS specialists during this phase. Given the varying mobility levels among people with MS, we will design social interaction within the telegaming system to accommodate both synchronous and asynchronous modes of play. Synchronous multiplayer interactions may be suitable for patients with higher functional capacity, while asynchronous modes — such as turn-based gameplay or shared virtual environments — will be explored to ensure inclusivity across a wider range of physical capabilities. We will determine the appropriate interaction modes for each game task during the design phase in consultation with patients, caregivers, and MS specialists. These workshops will also serve as an opportunity to define and refine the measurement models for each latent construct — such as motor function, cognitive processing speed, and social cognition — in collaboration with MS specialists, patients and their caregivers. Establishing these models early in the development process will ensure that the selected game tasks and biomarker indicators are grounded in clinically meaningful constructs and aligned with established assessment frameworks, as outlined in Table 1. The resulting prototypes will undergo iterative refinement to achieve a stable and usable system architecture suitable for further evaluation.

Biomarker Development Phase 2: Following the design phase, the project will focus on transforming gameplay telemetry into interpretable digital biomarkers. This work will include the development of algorithms to extract reaction latencies, coordination measures, temporal movement features, and indicators of cooperative behavior. Special attention will be given to creating features that are robust to variations in home environments and consumer-grade hardware. This technical component will produce the computational foundation required for examining how behavioral patterns relate to medication response and overall patient well-being.

Since the system collects data from each patient over an extended period, the analysis can track how an individual's biomarkers change over time, rather than simply comparing averages across patients. This within-individual longitudinal approach, using methods such as mixed-effects models (Bates et al. 2015), will enable the system to detect meaningful changes in a single patient's functioning in response to treatment, even when patients differ substantially from one another. This individualized approach remains especially important in MS, where the disease varies widely between individuals, making population-level statistics a poor guide for individual care. By focusing on change within each person, the framework directly supports the N-of-1 precision care goal described earlier.

Clinical Validation Phase 3: Building on the game tasks and biomarker indicators established during the design phase, the system will undergo iterative development until it reaches functional stability, defined here as achieving a task completion rate of 90% or above across test sessions and consistent data recording fidelity with no missing or corrupted biomarker streams. We will conduct home-based feasibility studies only after the game tasks meet this threshold, ensuring that the system is sufficiently reliable to support meaningful data collection in real-world environments. We will conduct feasibility studies in real home environments to assess usability, safety, patient acceptance, and data fidelity. These studies will provide insights into the validity of the system and reveal potential barriers to long-term adoption. Building on feasibility results, the project will conduct preliminary validation by comparing telegaming-derived biomarkers with established in-clinic motor assessments and caregiver reports. This phase will evaluate reliability across multiple sessions within individuals, convergent validity against established clinical measures outlined in Table 1, and responsiveness to treatment-related changes, laying the groundwork for subsequent large-scale clinical evaluation. We will assess reliability through repeated measurement sessions within individuals, with spe-

cific metrics to be determined during the design phase in consultation with MS specialists. Candidate metrics include intraclass correlation coefficients across sessions and raters, and test-retest reliability indices assessed over clinically meaningful intervals, e.g., days to weeks, aligned with known MS symptom fluctuation patterns. We will evaluate convergent validity by comparing telegaming-derived biomarkers against established in-clinic assessments, as outlined in Table 1, with the precise selection of reference measures finalized during design.

Conclusion

This report outlines a research agenda and plan for developing a clinically validated, home-based telegaming system capable of generating digital biomarkers that support precision care for individuals living with MS. By shifting assessment beyond the constraints of brief clinical visits and into patients' daily environments, the proposed approach has the potential to reveal motor, sensory, and social–behavioral dimensions of functioning that are systematically underrepresented in conventional in-clinic evaluations. The integration of gameplay-derived digital biomarkers offers a pathway toward earlier identification of suboptimal treatment response, improved longitudinal monitoring of quality-of-life outcomes, and more informed decisions regarding the continuation or adjustment of costly disease-modifying therapies.

Importantly, this research aims to bridge clinical neuroscience, rehabilitation science, and human–computer interaction by repositioning telegaming not merely as a therapeutic tool, but as a rigorous assessment modality with ecological validity and patient-centered design at its core. The proposed three-phase development plan — encompassing design, biomarker algorithm development, and feasibility and validation studies — provides a structured and scientifically grounded pathway toward a system that is both clinically meaningful and deployable in real-world settings. The participation of MS specialists, rehabilitation specialists, patients, and caregivers will position the system to reflect the lived experiences of its target users while meeting the rigorous standards required for clinical adoption.

Beyond its immediate contributions, this work addresses broader challenges in MS care. The ability to monitor patients continuously in their home environments may enable earlier detection of disease progression and treatment failure, reducing the period during which patients are exposed to ineffective and costly therapies.Furthermore, by leveraging accessible consumer technologies, the proposed framework supports international efforts to reduce disparities in MS care, offering a scalable and patient-centered monitoring solution across diverse healthcare systems.

This work will contribute to an emerging paradigm in which continuous, context-rich behavioral data complement traditional clinical measures, empowering clinicians with actionable insights and offering patients engaging, non-stigmatizing ways to actively participate in their own care. Ultimately, the proposed clinical telegaming system has the potential to enhance therapeutic decision-making, reduce unnecessary healthcare expenditure, and improve long-term quality of life for individuals living with MS, advancing the broader goal of precision, data-driven, and patient-centered neurological care.

Citation

Brainiacs Journal 2025 Volume 6 Issue 3 Edoc B3D757EF9.
Title: "From Play to Precision Care: Clinical Telegaming Biomarkers to Evaluate Medication Efficacy for Improving Multiple Sclerosis Patients' Quality of Life".
Authors: Kento Shigyo, Adam Craig, Carl Taswell.
Dates: created 2025-09-16, presented 2025-10-09, updated 2025-12-17, published 2025-12-17, revised 2026-06-07

Contact: kshigyo@bhavi.us
NPDS: LINKS/Brainiacs/Shigyo2025FPTPC
DOI: 10.48085/B3D757EF9

Affiliations

Brain Health Alliance Virtual Institute, www.BHAVI.us, Ladera Ranch, California, USA.

References

[1] M. Adiwangsa, H. Suominen, and P. Sweetser. "Can Augmented Reality Head-Mounted Display Exergames Support the Management of Multiple Sclerosis at Home? Workshop Discussions with Researchers and Experts with Lived Experience of MS." In: *Proceedings of the Extended Abstracts of the CHI Conference on Human Factors in Computing Systems*. 2025, pp. 1–7. DOI: 10.1145/3706599.3720214 (cited pp. 3, 5).

[2] S. Baron-Cohen, S. Wheelwright, J. Hill, Y. Raste, and I. Plumb. "The "Reading the Mind in the Eyes" Test revised version." *Journal of Child Psychology and Psychiatry* 42.3 (2001), pp. 241–251. DOI: 10.1111/1469-7610.00715 (cited p. 4).

[3] D. Bates, M. Mächler, B. Bolker, and S. Walker. "Fitting linear mixed-effects models using lme4." *Journal of statistical software* 67 (2015), pp. 1–48. DOI: 10.18637/jss.v067.i01 (cited p. 5).

[4] B. F. Bebo, M. Allegretta, D. Landsman, K. M. Zackowski, et al. "Pathways to cures for multiple sclerosis: A research roadmap." *Multiple Sclerosis Journal* 28.3 (2022), pp. 331–345. DOI: 10.1177/13524585221075990 (cited p. 3).

[5] R. Benedict et al. "Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis." *Multiple Sclerosis Journal* 23.5 (2017), pp. 721–733. DOI: 10.1177/1352458517690821 (cited p. 4).

[6] K. O. Berg, S. L. Wood-Dauphinee, J. I. Williams, and B. Maki. "Measuring balance in the elderly: Development and validation of an instrument." *Canadian Journal of Public Health* 83.S2 (1992), S7–S11. URL: https://escholarship.mcgill.ca/concern/theses/9k41zg16n (cited p. 4).

[7] R. M. Califf. "Biomarker definitions and their applications." *Experimental biology and medicine* 243.3 (2018), pp. 213–221. DOI: 10.1177/1535370217750088 (cited p. 2).

[8] A. Coravos, S. Khozin, and K. D. Mandl. "Developing and adopting safe and effective digital biomarkers to improve patient outcomes." *NPJ digital medicine* 2.1 (2019), p. 14. DOI: 10.1038/s41746-019-0090-4 (cited p. 2).

[9] M. Dalmazane, M. Gallou-Guyot, M. Compagnat, L. Magy, A. Montcuquet, M. Billot, J.-C. Daviet, and A. Perrochon. "Effects on gait and balance of home-based active video game interventions in persons with multiple sclerosis: a systematic review." *Multiple sclerosis and related disorders* 51 (2021), p. 102928. DOI: 10.1016/j.msard.2021.102928 (cited p. 3).

[10] R. K. Dhamija, A. Saluja, D. Garg, S. Chauhan, et al. "Teleneurorehabilitation and motor and nonmotor symptoms and quality of life in Parkinson disease: the TELEPARK randomized clinical trial." *JAMA neurology* 82.4 (2025), pp. 376–383. DOI: 10.1001/jamaneurol.2024.5387 (cited p. 3).

[11] A. Dillenseger, M. L. Weidemann, K. Trentzsch, H. Inojosa, et al. "Digital biomarkers in multiple sclerosis." *Brain sciences* 11.11 (2021), p. 1519. DOI: 10.3390/brainsci11111519 (cited p. 2).

[12] S. Dutta, K. Uhegbu, S. Nori, S. Mashkoor, S. K. Taswell, and C. Taswell. "DREAM Principles from the PORTAL-DOORS Project and NPDS Cyberinfrastructure." In: *2020 IEEE 14th International Conference on Semantic Computing (ICSC)*. IEEE, Feb. 4, 2020, pp. 211–216. DOI: 10.1109/ICSC.2020.00044. URL: https://www.portaldoors.org/pub/docs/ICSC2020PDPDREAM191222.pdf (cited p. 3).

[13] J. Fischer, R. Rudick, G. Cutter, S. Reingold, and N. M. S. C. O. A. T. Force. "The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment." *Multiple Sclerosis Journal* 5.4 (1999), pp. 244–250. DOI: 10.1177/135245859900500409 (cited p. 4).

[14] A. Friedrich. *The Multiple Sclerosis Companion*. Springer, 2023. DOI: 10.1007/978-3-662-67540-3 (cited p. 1).

[15] S. Gómez-Melero, J. Caballero-Villarraso, B. M. Escribano, A. Galvao-Carmona, I. Túnez, and E. Agüera-Morales. "Impact of Cognitive Impairment on Quality of Life in Multiple Sclerosis Patients—A Comprehensive Review." *Journal of Clinical Medicine* 13.11 (2024), p. 3321. DOI: 10.3390/jcm13113321 (cited p. 1).

[16] D. S. Goodin, E. Frohman, G. Garmany, J. Halper, W. Likosky, F. Lublin, et al. "Disease modifying therapies in multiple sclerosis." *Neurology* 58.2 (2002), pp. 169–178. URL: http://www.neurology.org/cgi/content/full/58/2/169 (cited p. 1).

[17] C. V. Granger, B. B. Hamilton, R. A. Keith, M. Zielezny, and F. S. Sherwin. "Advances in functional assessment for medical rehabilitation." *Topics in Geriatric Rehabilitation* 1.3 (1986), pp. 59–74. DOI: 10.1097/00013614-198604000-00007 (cited p. 4).

[18] E. S. Gromisch, J. Imitola, T. Agresta, A. P. Turner, et al. "Mobile-based cognitive screening tools in multiple sclerosis: Scoping literature and app store review." *Multiple Sclerosis and Related Disorders* (2025), p. 106782. DOI: 10.1016/j.msard.2025.106782 (cited p. 3).

[19] F.-N. B. W. Group et al. "BEST (biomarkers, EndpointS, and other tools) resource [internet]" (2016). URL: https://pubmed.ncbi.nlm.nih.gov/27010052/ (cited p. 2).

[20] D. M. Hartung. "Economics of multiple sclerosis disease-modifying therapies in the USA." *Current Neurology and Neuroscience Reports* 21.7 (2021), p. 28. DOI: 10.1007/s11910-021-01118-x (cited p. 2).

[21] M. K. Holden, T. A. Dyar, and L. Dayan-Cimadoro. "Telerehabilitation using a virtual environment improves upper extremity function in patients with stroke." *IEEE transactions on neural systems and rehabilitation engineering* 15.1 (2007), pp. 36–42. DOI: 10.1109/TNSRE.2007.891388 (cited p. 2).

[22] C. Jadhav, P. Nair, and V. Krovi. "Individualized interactive home-based haptic telerehabilitation." *IEEE MultiMedia* 13.3 (2006), pp. 32–39. DOI: 10.1109/MMUL.2006.60 (cited p. 2).

[23] J. Jonsdottir, R. Bertoni, M. Lawo, A. Montesano, T. Bowman, and S. Gabrielli. "Serious games for arm rehabilitation of persons with multiple sclerosis. A randomized controlled pilot study." *Multiple sclerosis and related disorders* 19 (2018), pp. 25–29. DOI: 10.1016/j.msard.2017.10.010 (cited p. 3).

[24] R. Kapoor, K. E. Smith, M. Allegretta, D. L. Arnold, et al. "Serum neurofilament light as a biomarker in progressive multiple sclerosis." *Neurology* 95.10 (2020), pp. 436–444. DOI: 10.1212/WNL.0000000000010346 (cited p. 3).

[25] D. Lockery, J. F. Peters, and C. Taswell. "CTGaming: A Problem-Oriented Registry for Clinical TeleGaming Rehabilitation and Intervention." *Journal of Emerging Technologies in Web Intelligence* 3.1 (Feb. 2011), pp. 28–37. DOI: 10.4304/JETWI.3.1.28-37 (cited pp. 2, 3).

[26] M. G. Maggio, F. Baglio, F. Arcuri, F. Borgnis, et al. "Cognitive telerehabilitation: An expert consensus paper on current evidence and future perspective." *Frontiers in Neurology* 15 (2024), p. 1338873. DOI: 10.3389/fneur.2024.1338873 (cited p. 3).

[27] X. Montalban, C. Lebrun-Frénay, J. Oh, G. Arrambide, et al. "Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria." *The Lancet Neurology* 24.10 (Oct. 2025), pp. 850–865. ISSN: 1474-4422. DOI: 10.1016/s1474-4422(25)00270-4 (cited p. 3).

[28] V. D. Morra et al. "The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care – updates at the 2023 plenary event." *Frontiers in Neurology* 15 (2024), p. 1407257. DOI: 10.3389/fneur.2024.1407257 (cited p. 3).

[29] Y. Oh and S. Yang. "Defining exergames & exergaming." *Proceedings of meaningful play* 2010 (2010), pp. 21–23. URL: https://www.researchgate.net/profile/Stephen-Yang-9/publication/230794344_Defining_exergames_exergaming/links/0fcfd5047ab31e6cde000000/Defining-exergames-exergaming.pdf?utm_medium=email&utm_source=transaction (cited p. 3).

[30] R. Ortiz Gutierrez, F. Galán del Río, R. Cano de la Cuerda, I. M. Alguacil-Diego, R. Arroyo González, and J. C. Miangolarra Page. "A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients." *NeuroRehabilitation* 33.4 (2013), pp. 545–554. DOI: 10.3233/NRE-130995 (cited p. 3).

[31] L. Pathak. "Personalized treatment for multiple sclerosis: the role of precision medicine." *Neurology Letters* 2.1 (2023), pp. 30–34. DOI: 10.52547/nl.2.1.30 (cited p. 1).

[32] A. Peretti, F. Amenta, S. K. Tayebati, G. Nittari, and S. S. Mahdi. "Telerehabilitation: review of the state-of-the-art and areas of application." *JMIR rehabilitation and assistive technologies* 4.2 (2017), e7511. DOI: 10.2196/rehab.7511 (cited p. 3).

[33] S. Pless, T. Woelfle, J. Lorscheider, A. Wiencierz, et al. "CoGames: development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in multiple sclerosis." *Journal of Neurology* 272.2 (2025), p. 119. DOI: 10.1007/s00415-024-12818-y (cited p. 3).

[34] S. Pless, T. Woelfle, Y. Naegelin, J. Lorscheider, A. Wiencierz, Ó. Reyes, P. Calabrese, and L. Kappos. "Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study." *Journal of Neurology* 270.7 (2023), pp. 3451–3463. DOI: 10.1007/s00415-023-11671-9 (cited p. 3).

[35] D. Podsiadlo et al. "The timed "Up & Go": a test of basic functional mobility for frail elderly persons." *Journal of the American Geriatrics Society* 39.2 (1991), pp. 142–148. DOI: 10.1111/j.1532-5415.1991.tb01616.x (cited p. 4).

[36] L. Prosperini, F. Fanelli, N. Petsas, E. Sbardella, et al. "Multiple sclerosis: changes in microarchitecture of white matter tracts after training with a video game balance board." *Radiology* 273.2 (2014), pp. 529–538. DOI: 10.1148/radiol.14140168 (cited p. 3).

[37] R. M. Reitan. "Validity of the Trail Making Test as an indicator of organic brain damage." *Perceptual and Motor Skills* 8.3 (1958), pp. 271–276. DOI: 10.2466/pms.1958.8.3.271 (cited p. 4).

[38] T. Schmitz-Hübsch et al. "Scale for the assessment and rating of ataxia: development of a new clinical scale." *Neurology* 66.11 (2006), pp. 1717–1720. DOI: 10.1212/01.wnl.0000219042.60538.92 (cited p. 4).

[39] N. Sharma, A. Yadav, M. Kaur, P. Kumar, S. Kaur, G. Kapoor, and M. Verma. "Group tele-rehabilitation improves quality of life among subjects with Parkinson's disease: A two arm non-parallel non-randomized clinical trial." *Parkinsonism & Related Disorders* 121 (2024). DOI: 10.1016/j.parkreldis.2024.106027 (cited p. 3).

[40] S. Shiffman, A. A. Stone, and M. R. Hufford. "Ecological momentary assessment." *Annu. Rev. Clin. Psychol.* 4.1 (2008), pp. 1–32. DOI: 10.1146/annurev.clinpsy.3.022806.091415 (cited p. 2).

[41] A. J. Solomon, R. A. Marrie, S. Viswanathan, et al. "Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition." *Neurology* 101.3 (2023), e294–e304. DOI: 10.1212/WNL.0000000000207481 (cited p. 3).

[42] C. Taswell. "DOORS to the Semantic Web and Grid with a PORTAL for Biomedical Computing." *IEEE Transactions on Information Technology in Biomedicine* 12.2 (2 Mar. 2007). In the Special Section on Bio-Grid published online 3 Aug. 2007, pp. 191–204. ISSN: 1089-7771. DOI: 10.1109/TITB.2007.905861 (cited p. 3).

[43] C. Taswell. "A Distributed Infrastructure for Metadata about Metadata: The HDMM Architectural Style and PORTAL-DOORS System." *Future Internet* 2.2 (2010). In Special Issue on Metadata and Markup., pp. 156–189. ISSN: 1999-5903. DOI: 10.3390/FI2020156. URL: https://www.mdpi.com/1999-5903/2/2/156/ (cited p. 3).

[44] C. Taswell. "A New PDS PORTAL for Clinical TeleGaming Rehabilitation and Intervention." In: *2010 IEEE International Conference on Bioinformatics and Biomedicine Workshops (BIBMW)*. IEEE, Dec. 2010. DOI: 10.1109/BIBMW.2010.5703953 (cited pp. 2, 3).

[45] WHOQOL Group. "Development of the WHOQOL: Rationale and current status." *International Journal of Mental Health* 23.3 (1994), pp. 24–56. ISSN: 1557-9328. DOI: 10.1080/00207411.1994.11449286 (cited p. 2).

[46] L. Xu, S. Loh, and C. Taswell. "Web-Enabled Software for Clinical Telegaming Evaluation of Multisensory Integration and Response to Auditory and Visual Stimuli." In: *Neural Engineering (NER), 2015 7th International IEEE/EMBS Conference on*. IEEE, Apr. 2015, pp. 739–742. DOI: 10.1109/NER.2015.7146729 (cited pp. 2, 3).

